Development of a Prognostic Five-Gene Signature with Radiotherapy Guidance Significance for Diffuse Lower-Grade Glioma Patients Based on Large-Scale Sequencing Data

Qiang Zhang,Shun-Bin Luo,Fu-Chen Xie,Xiao-Jun Liu,Ren-ai Xu

DOI: https://doi.org/10.21203/rs.3.rs-32321/v1

2020-06-05

Abstract:Abstract Background: Diffuse lower-grade gliomas (LGGs) are infiltrative and heterogeneous neoplasms. Gene signature including multiple protein coding genes (PCGs) is widely used as tumor markers. This study aimed to construct a multi-PCG signature to predict survival for LGG patients. Methods: LGG data including PCG expression profiles and clinical information were downloaded from The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA). Survival analysis, receiver operating characteristic (ROC) analysis and random survival forest algorithm (RSFVH) were used to identify the prognostic PCG signature. Results: From the training ( n = 524) and test ( n = 431) datasets, a five-PCG signature which can classify LGG patients into low- or high-risk group with significantly different overall survival (Log Rank P < 0.001) was screened out and validated. In terms of prognosis predictive performance, the five-PCG signature is stronger than other clinical variables and IDH mutation status. Moreover, the five-PCG signature could further divide radiotherapy patients into two different risk groups. GO and KEGG analysis found PCGs in the prognostic five-PCG signature were mainly enriched in cell cycle, apoptosis, DNA replication pathways. Conclusions: The new five-PCG signature is a reliable prognostic marker with radiotherapy guidance significance for LGG patients and has a good prospect in clinical application.